ABOUT NOVUSTEX
Making human tissue biology reproducible enough to buy.
NovusTex productizes human-relevant tissue biology into standardized, procurement-ready preclinical models — starting with NasalCart™ for intranasal development. We are a human-relevant preclinical infrastructure company, not a printer company.
HOW WE OPERATE
Evidence before expansion.
Narrow the claim
A defined context of use makes the first product reproducible, auditable and useful.
Lock the gate
Every phase has pre-specified pass, iterate and stop criteria.
Preserve the rights
Portable specifications, raw data and SOPs keep the product independent of any single vendor.
Earn the next phase
Biological complexity is added only when it changes a customer's decision.
DESIGN FOUNDATION
100+
publications screened
18+
design parameters normalized
23+
construct configurations mapped
7
prototype workflows assembled
LEADERSHIP
Founder-led science. Asset-light execution.
Dr. Sahil Khan
FOUNDER & CEO
MBBS, MS Biotechnology (Johns Hopkins). Physician-scientist with translational research in critical care and regenerative medicine; Johns Hopkins lecturer (2023–2026). Leads scientific strategy, product specifications, assay requirements and customer discovery.
LinkedIn
Ryan Idnani
CO-FOUNDER & CTO
Biomedical engineering background (UC Berkeley / Johns Hopkins). Co-authored translational bioengineering work with Sahil. Leads product architecture, technical coordination, manufacturing integration and development execution.
LinkedInCONTACT
Pilots, partnerships and investor conversations.
Tell us about your intranasal program or your interest in NovusTex. Investor materials are shared on request.